Mount Sinai IMPACC COVID-19 Cores

作为NIAID/DAIT倡议的一部分，我们被选中参加一个多中心项目，即 新冠肺炎队列中的免疫表型评估，旨在收集和分配患者 对2000例柯萨奇病毒19例患者免疫应答进行检测和分析 核心。这项全国性的免疫表型鉴定协议在高影响力的新冠肺炎地区的主要目的是 对可能预测或易感的宿主因素进行详细的免疫表型鉴定和分析 解决感染与疾病进展及其后果的关系。该协议的设计目的是 告知疾病进展动态和相关生物标志物；并进行详细的、纵向的 免疫表型(通过疾病进展呈现)，包括病毒载量的测量 了解病毒载量和免疫病理在疾病进展中的相互作用。有一个 通过包括将需要的临床特征的所有方面来强调临床进展 将免疫病理机制与每个患者的每个疾病阶段相匹配。IMPACC建立在队列的基础上 和由NAAD/DAIT资助的人类临床中心开发的临床资源和技术 免疫学联合会(CCHI)和人类免疫学项目联合会(HIPC)。因此，我们的团队一直在 被DAIT选中参加，因为费尔南德斯-塞斯马博士目前是一个重债穷国中心的PI， 名为DHIPC，研究人类对登革热、基孔肯雅和寨卡病毒感染的免疫反应 和疫苗接种，Adeeb Rahman博士也是同一个重债穷国中心的重要成员，并将成为 此应用程序的免疫表型核心领导者。此外，团队的其他成员已经被 根据他们在医院临床样本采集和处理方面的专业知识被选中参加 分析对呼吸道病毒感染的反应的设置，包括病毒测序和病毒载量 测量。因此，这项对我们的母公司重债穷国赠款的行政补充，名为Mt Sinai IMPACC是 在我们的母公司HIPC奖的范围内，因为它专注于研究人类对 病毒感染。为这项应用而聚集的团队包括领导临床/样本的Viviana Simon博士 收集核心，Adeb Rahman博士，将领导免疫表型核心，Florian Krammer博士，领导 血清学核心，领导病毒测序核心的哈姆·范·巴克尔博士和阿道夫·加西亚博士- 萨斯特是该诊所的合作研究员，詹姆·胡克博士是一名肺科医生。与这支球队和 临床样本的可用性以及我们现场的适当资源和生物遏制措施 提供样本并分析不同的免疫和病毒参数，以帮助我们了解 COVID19大流行期间的疾病严重程度和进展。西奈山医院位于纽约 纽约市是美国这场大流行的震中，已经在治疗数百例COVID 病人。

As part of an NIAID/DAIT initiative we have been selected to participate in a multicenter project, namely Immunophenotyping assessment in a COVID-19 Cohort (IMPACC), aimed to collect and distribute patient samples and to and analyze the immune responses of 2000 COVID19 patients using specific designated cores. The main purpose of this nationwide immunophenotyping protocol in high impact COVID-19 areas is to perform detailed immunophenotyping and analysis of the host factors that may predict or predispose to resolution of infection versus disease progression and its consequences. The protocol has been designed to inform disease progression dynamics and related biomarkers; and conduct detailed, longitudinal immunophenotyping (presentation through disease progression) that includes measures of viral load to understand the interplay between viral load and immune pathology in disease progression. There is an emphasis on the clinical progression by including all aspects of clinical characterization that will be needed to match immunopathogenesis with each disease stage within each patient. IMPACC builds on the cohorts and clinical resources and technology developed by the NAIAD/DAIT funded Clinical centers for Human Immunology (CCHI) and the Human Immunology Project Consortia (HIPC). Thus, our team has been selected by DAIT to participate, since Dr. Fernandez-Sesma is currently the PI of one of the HIPC centers, named DHIPC, which studies human immune responses to dengue, chikungunya and Zika virus infection and vaccination and Dr. Adeeb Rahman is also a crucial member of the same HIPC center and will be the Immonophenotyping core leader for this application. Additionally, other members of the team have been selected to participate based on their expertise in clinical sample collection and processing in hospital settings to analyze responses to respiratory viral infections, including viral sequencing and viral load measurement. Thus, this administrative supplement to our parent HIPC grant, named Mt Sinai IMPACC is within the scope of our parent HIPC award, since it is focused on the study of human immune responses to a viral infection. The team gathered for this application includes Dr. Viviana Simon, leading the clinical/sample collection core, Dr. Adeb Rahman, that will lead the immunopheotyping core, Dr. Florian Krammer, leading the serology Core, Dr. Harm Van Bakel, leading the virus sequencing core as well as Dr. Adolfo Garcia- Sastre as a co-investigator and Dr. Jaime Hook as a pulmonologist in the clinic. With this team and the availability of clinical samples and the appropriate resources and biocontainment at our site we are poised to provide samples and to analyze the different immune and viral parameters that will help us understand disease severity and progression in during the COVID19 pandemic. Mount Sinai Hospital is located in New York City, which is at the epicenter of this pandemic in the US and is already treating hundreds of COVID patients.